GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteomics International Laboratories Ltd (ASX:PIQ) » Definitions » EBITDA Margin %

Proteomics International Laboratories (ASX:PIQ) EBITDA Margin % : -585.28% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Proteomics International Laboratories EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Proteomics International Laboratories's EBITDA for the six months ended in Dec. 2023 was A$-3.62 Mil. Proteomics International Laboratories's Revenue for the six months ended in Dec. 2023 was A$0.62 Mil. Therefore, Proteomics International Laboratories's EBITDA margin for the quarter that ended in Dec. 2023 was -585.28%.


Proteomics International Laboratories EBITDA Margin % Historical Data

The historical data trend for Proteomics International Laboratories's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteomics International Laboratories EBITDA Margin % Chart

Proteomics International Laboratories Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only -127.04 -96.35 -189.70 -305.98 -1,135.21

Proteomics International Laboratories Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -457.43 -189.92 -495.96 12,116.22 -585.28

Competitive Comparison of Proteomics International Laboratories's EBITDA Margin %

For the Biotechnology subindustry, Proteomics International Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proteomics International Laboratories's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Proteomics International Laboratories's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Proteomics International Laboratories's EBITDA Margin % falls into.



Proteomics International Laboratories EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Proteomics International Laboratories's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-8.287/0.73
=-1,135.21 %

Proteomics International Laboratories's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-3.617/0.618
=-585.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Proteomics International Laboratories  (ASX:PIQ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Proteomics International Laboratories EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Proteomics International Laboratories's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Proteomics International Laboratories (ASX:PIQ) Business Description

Traded in Other Exchanges
N/A
Address
6 Verdun Street, QEII Medical Centre, QQ Block, Nedlands, Perth, WA, AUS, 6009
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.

Proteomics International Laboratories (ASX:PIQ) Headlines

No Headlines